149 related articles for article (PubMed ID: 16489072)
1. Profiling markers of prognosis in colorectal cancer.
Lyall MS; Dundas SR; Curran S; Murray GI
Clin Cancer Res; 2006 Feb; 12(4):1184-91. PubMed ID: 16489072
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.
Tornillo L; Lugli A; Zlobec I; Willi N; Glatz K; Lehmann F; Spichtin HP; Maurer R; Stoios D; Sauter G; Terracciano L
Am J Clin Pathol; 2007 Jan; 127(1):114-23. PubMed ID: 17145638
[TBL] [Abstract][Full Text] [Related]
5. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
Zlobec I; Baker K; Terracciano LM; Lugli A
Clin Cancer Res; 2008 Jun; 14(12):3798-806. PubMed ID: 18559599
[TBL] [Abstract][Full Text] [Related]
6. Analysis of key cell-cycle checkpoint proteins in colorectal tumours.
McKay JA; Douglas JJ; Ross VG; Curran S; Loane JF; Ahmed FY; Cassidy J; McLeod HL; Murray GI
J Pathol; 2002 Apr; 196(4):386-93. PubMed ID: 11920733
[TBL] [Abstract][Full Text] [Related]
7. Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1.
Li M; Li JY; Zhao AL; He JS; Zhou LX; Li YA; Gu J
Dis Colon Rectum; 2007 Nov; 50(11):1887-98. PubMed ID: 17882488
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
Makretsov NA; Huntsman DG; Nielsen TO; Yorida E; Peacock M; Cheang MC; Dunn SE; Hayes M; van de Rijn M; Bajdik C; Gilks CB
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6143-51. PubMed ID: 15448001
[TBL] [Abstract][Full Text] [Related]
9. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients.
Ullenhag GJ; Mukherjee A; Watson NF; Al-Attar AH; Scholefield JH; Durrant LG
Clin Cancer Res; 2007 Sep; 13(17):5070-5. PubMed ID: 17785559
[TBL] [Abstract][Full Text] [Related]
11. Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma.
Xu F; Wang F; Di M; Huang Q; Wang M; Hu H; Jin Y; Dong J; Lai M
Clin Cancer Res; 2007 Sep; 13(17):5082-8. PubMed ID: 17785561
[TBL] [Abstract][Full Text] [Related]
12. Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance.
Nishihara K; Shomori K; Fujioka S; Tokuyasu N; Inaba A; Osaki M; Ogawa T; Ito H
Int J Oncol; 2008 Aug; 33(2):245-51. PubMed ID: 18636144
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer.
Oshima CT; Iriya K; Forones NM
Neoplasma; 2005; 52(5):420-4. PubMed ID: 16151588
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.
Kumarakulasingham M; Rooney PH; Dundas SR; Telfer C; Melvin WT; Curran S; Murray GI
Clin Cancer Res; 2005 May; 11(10):3758-65. PubMed ID: 15897573
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic significance and clinic utility of serum and immunohistochemical cathepsin B levels in colorectal cancer].
Padilla D; Cubo T; Molina JM; García M; De la Osa G; Palomino T; Pardo R; Martín J; Arévalo E; Hernández Calvo J
An Med Interna; 2003 Oct; 20(10):521-5. PubMed ID: 14585038
[TBL] [Abstract][Full Text] [Related]
17. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
[TBL] [Abstract][Full Text] [Related]
18. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between p27 expression and prognosis of colorectal carcinoma].
Chen AJ; Meng QH; Long B; Yang GL
Ai Zheng; 2002 Oct; 21(10):1075-7. PubMed ID: 12508646
[TBL] [Abstract][Full Text] [Related]
20. SMAD4 as a prognostic marker in colorectal cancer.
Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
